

Announcement

To the Copenhagen Stock Exchange and the press

*Nørresundby, Denmark, 4 September 2002
Stock Exchange announcement no. 13/2002
Number of pages: 3*

RTX Telecom and Thomsen Bioscience develop a portable sensor for the detection of biological weapons and infectious diseases

- **The partnership provides an opportunity to develop a rapid, accurate and inexpensive surveillance system for customers such as the armed forces, civil defence and veterinary authorities**
- **It is expected that the first product will be available in 12–18 months**
- **The project strengthens RTX Telecom's strategic position in the field of applied wireless communication solutions.**

With an investment of DKK 3 million in the biotech company Thomsen Bioscience A/S, RTX Telecom is taking the first step towards applying its expertise in wireless communication technology to the transfer of important gathered biological data.

In cooperation with Thomsen Bioscience, RTX Telecom aims to develop portable sensor units that can rapidly and effectively detect various types of air-borne spores, bacteria and virus and subsequently transmit the gathered data to another party.

About Thomsen Bioscience

Thomson Bioscience is a development company with a focus on the incorporation of advanced biological methods in biochips. This involves the gathering of biological organisms down to the single cell level, preparing these organisms for biochemical analysis, molecular extraction, separation and purification followed by the registration of biochemical activity, data processing and data collection. These processes are integrated in autonomous miniature laboratories in the form of biochips – also known as an intelligent “lab-on-a-chip”. The technology can be used for the detection of biological weapons, the clinical diagnosis of infectious diseases and the development of pharmaceutical products.

RTX Telecom A/S
Strømmen 6
DK-9400 Nørresundby,
Danmark
Tel : +45 96 32 23 00
Fax : +45 96 32 23 10
VAT# : DK 17 00 21 47
Web : www.rtx.dk
E-mail : info@rtx.dk

Compared with other biotechnological forms of analysis, detection via intelligent “lab-on-a-chip” solutions is a sensitive, accurate, rapid and inexpensive method. The technology can therefore form part of active biological alertness programmes with timely detection and warning about harmful biological substances, which in turn allows preventative measures to be taken at an earlier stage and with greater success. It is likely that this technology can be incorporated in portable equipment, which opens up completely new avenues for the rapid and accurate detection of sources of infection.

Thomsen Bioscience was founded in September 2001 by Lars Thomsen, PhD. The company’s development activities have thus far been financed with the support of the Danish *Vækstfonden* business development finance organisation and Novi Innovation A/S.

The cooperation agreement between Thomsen Bioscience and RTX Telecom stipulates that the former will be responsible for the biotechnological development whereas the latter will be in charge of project management and the development of the wireless communication solution.

RTX Telecom’s investment is financed by the issue of new shares in Thomsen Bioscience whereby RTX Telecom obtains a 17% share in the company (after dilution). The agreement also contains a provision for additional investments within a two-year time frame. The purchase price of the shares will be paid in cash.

Thomsen Bioscience has rented premises at RTX Telecom’s head office at Strømmen 6, Nørresundby.

Investment background

The investment in Thomsen Bioscience is in accordance with RTX Telecom’s ongoing programme of assessment and implementation of possible strategically advantageous acquisitions, in cases where such purchases provide access to additional staff resources and/or key technologies that contribute to the fulfilment of the company’s overall objectives.

RTX Telecom’s strategic position is expected to improve as a result of this investment, as it adds new market sectors to the company’s existing markets. As a result of this investment, the group is expected to become active in new markets that include the armed forces, civil defence and veterinary authorities in Denmark and abroad as well as in the medico-technical equipment and health care industries.

RTX Telecom expects the partnership with Thomsen Bioscience to create new market opportunities for RTX Telecom’s current technological platforms, including DECT, CDMA2000, GSM/GPRS, Bluetooth™ and IEEE802.11 a/b. Together, RTX Telecom and Thomsen Bioscience expect to be able to carry out extremely advanced development projects, especially in technologies requiring high levels of expertise.

Accounting

Shares in Thomsen Bioscience will be entered in the RTX Telecom balance sheet as securities under financial fixed assets. The shares will be valued on the basis of an approximate current share price, or the purchase price, if it does not prove possible to calculate an approximate current share price.

Any profit or loss stemming from the price of the shares, whether realised or not, will be included in the profit and loss statement under the items "Financial income" or "Financial expenses". Any dividend on the shares will be entered as income under the item "Financial income" in the financial year in which the dividend was declared.

Expectations regarding earnings

RTX Telecom's investment in Thomsen Bioscience will not have any significant effect on expectations as regards profits for the current 2001/02 financial year.

Implementation of the agreement

The implementation of the agreement is dependent on some straightforward matters that are expected to be cleared up within a few days.

With regards,
RTX Telecom A/S

Jørgen Elbæk
Managing Director

Please contact managing director Jørgen Elbæk on +45 96 32 23 00 for answers to any questions and for further information.

The RTX Telecom Web site is at: www.rtx.dk
The Thomsen Bioscience Web site is at: www.thomsen-bioscience.com